Koninklijke Philips N.V. research snapshot
PHG AI stock analysis currently reads Koninklijke Philips as a healthcare technology turnaround with improving profitability, a large installed base in imaging and monitoring, and a 2026 plan built around productivity and platform innovation. The counterweight is meaningful net debt, Respironics-related regulatory and legal uncertainty, tariff exposure, and the need to turn order growth into durable cash flow. At the July 11, 2026 cutoff, the latest available July 8 close was $27.57 and price multiplied by 952.02 million shares implied market capitalization near $26.25 billion, close to the $26.15 billion reported market value. The PHG AI stock forecast is scenario-based, not a precise price prediction, and this page is informational research rather than investment advice.
Current price
$27.57
Market cap
$26.15 billion
AI score
64 / 100
Rating
Healthcare turnaround, execution and liability sensitive
Trend status
Above the 50-day average, testing the 200-day average
Data cutoff (updated weekly)
July 11, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Philips sells diagnostic imaging, image-guided therapy, patient monitoring, informatics, sleep and respiratory care, and personal health products to hospitals, clinicians, patients, and consumers. | High |
| Moat | The moat comes from regulated products, installed systems, clinical workflow integration, service relationships, patents, and global distribution. It is real but contested by larger medtech peers and requires quality execution. | Medium-high |
| Management | CEO Roy Jakobs is pursuing focused segment strategies, platform innovation, productivity, and quality improvement. Credibility depends on converting the plan into growth while resolving legacy issues without new surprises. | Medium |
| Financial trend | FY2025 sales were EUR 17.834 billion, income from operations was EUR 1.424 billion, and free cash flow was EUR 512 million. Q1 2026 delivered 4% comparable sales growth, a 9.0% adjusted EBITA margin, and EUR 28 million of free cash flow. | High |
| Valuation | At $27.57, financial_rigor.py calculated about 24.0x trailing EPS, 11.4x trailing free cash flow, a 3.05% dividend yield, and an 8.76% free-cash-flow yield using current data-provider inputs. | Medium |
| Technical trend | PHG was above the 50-day moving average of $26.61 but slightly below the 200-day moving average of $27.95, making the long-term trend a live confirmation test rather than an established breakout. | Medium |
| Risk level | Risk is high because Respironics proceedings, patient safety and quality, consent-decree compliance, tariffs, leverage, currency, and healthcare spending can materially affect earnings and valuation. | High |
| AI confidence | High for reported facts and arithmetic. Medium for forecast ranges because legal outcomes, regulatory requirements, and medical-device demand are not reliably predictable from past data. | High data confidence |
| Investment certainty | Medium-low certainty. The recovery is visible, but a durable investment case needs proof that operating progress exceeds the remaining balance-sheet and liability burden. | Medium-low |
PHG AI stock forecast
The PHG AI stock forecast uses scenario ranges around the $27.57 July 8 close rather than a point target. A financial_rigor.py three-scenario model using approximately $1.91 implied forward EPS produced mechanical three-year values near $45.80 in a bull case, $34.10 in a base case, and $19.70 in a bear case before dividends, currency moves, and execution risk.
$34 to $46
More likely if comparable sales hold in the 3% to 4.5% outlook range, adjusted EBITA reaches the 12.5% to 13.0% target range, free cash flow reaches EUR 1.3 to 1.5 billion, quality actions stay on track, and Respironics costs do not create new material setbacks.
$27 to $34
More likely if Philips delivers gradual margin and cash-flow improvement while tariffs, currency, and Connected Care pressure limit the pace of earnings growth and the market keeps a mid-teens forward earnings multiple.
$19 to $27
More likely if Respironics proceedings or quality costs rise, consent-decree execution slows, tariffs hurt margins, hospital capital spending weakens, or investors demand a lower multiple for a leveraged turnaround.
PHG AI technical analysis
PHG AI technical analysis starts from the $27.57 July 8, 2026 close. StockAnalysis listed a 50-day moving average of $26.61, a 200-day moving average of $27.95, RSI of 56.41, 20-day average volume of about 1.03 million shares, and a 52-week range of $23.75 to $33.44. These static levels must be refreshed against a live chart before any decision.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $27.57 | StockAnalysis listed this regular-session close on July 8, 2026. The July 11 cutoff follows the latest available quote snapshot. |
| Near support | $26.61 | StockAnalysis listed the 50-day moving average at this level. Sustained trading below it would weaken the recent recovery. |
| Deeper support | $23.75 | The 52-week low listed in the quote snapshot is a broader downside reference, not a stop recommendation. |
| Near resistance | $27.95 to $28.25 | The 200-day moving average was $27.95 and a Nasdaq snapshot reported an intraday move to $28.26 after PHG crossed that average. |
| Higher resistance | $33.44 | This was the listed 52-week high. A move through it would require confirmation from volume and fundamentals. |
| Momentum | Neutral to constructive | RSI was 56.41, with price above the 50-day average but near the 200-day average. |
| Volume | About 1.03M 20-day average shares | Breakouts are more credible when volume is materially above this reference and not driven only by currency or headline moves. |
| Volatility | Moderate market beta, high event risk | The listed five-year beta was 0.92, but earnings, legal, regulatory, and quality headlines can create gap risk beyond a beta measure. |
| Invalidation | Failure below $26.61, then $23.75 | A loss of the 50-day average followed by a move toward the 52-week low would invalidate a simple trend-recovery setup. |
PHG AI trading strategy
The PHG AI trading strategy is a non-personalized framework for a medical-technology turnaround. It should be used with position sizing, refreshed chart data, earnings dates, and independent review of legal and regulatory disclosures.
Monitor whether PHG holds above the $26.61 50-day average, reclaims the $27.95 to $28.25 long-term resistance area, and does so with volume above the 20-day average. Confirm the move with updated order intake, margins, and free-cash-flow guidance.
Treat a sustained failure below the 50-day average, a new quality or litigation shock, or reduced cash-flow guidance as conditions that invalidate the setup.
If PHG revisits the $26.61 support area while comparable sales, productivity, and the 2026 outlook remain intact, monitor whether buyers defend the level and reclaim the 200-day average.
Do not average down solely because the dividend yield rises. Reassess if the decline is tied to a material Respironics, consent-decree, tariff, or cash-flow development.
Track comparable sales by segment, adjusted EBITA margin, free cash flow, order intake, net debt, Diagnosis and Treatment demand, Connected Care profitability, tariffs, and all Respironics-related disclosures.
Reduce confidence if margin gains depend mainly on temporary cost actions while revenue, quality metrics, cash flow, or liability clarity deteriorate.
Investment research summary
Customers pay Philips for regulated medical technology, imaging and monitoring workflow, service, clinical confidence, and consumer health products. Revenue combines equipment, leasing, services, software, disposables, and consumer sales.
The moat rests on installed equipment, clinician workflow integration, regulatory know-how, patents, service relationships, and global scale. Its durability depends on product quality, innovation speed, and hospital purchasing cycles.
The failure path is a recovery that proves too expensive: new quality or legal costs, consent-decree delays, weak hospital demand, tariffs, and debt absorb the cash that should fund innovation and shareholder returns.
Roy Jakobs has centered the plan on segment focus, AI-enabled platforms, productivity, supply-chain resilience, and quality. Management quality should be judged by repeated delivery against the 2026 outlook and transparent handling of legacy liabilities.
Aging populations, clinician shortages, and demand for productivity support the need for imaging, monitoring, data, and AI-assisted workflows. Competition, reimbursement, hospital budgets, and regulation limit how much of that demand becomes profit.
PHG offers an improving free-cash-flow profile and a 3.05% indicated dividend yield, but a trailing earnings multiple near 24x leaves less margin for execution failure than a distressed valuation would. The margin of safety depends on liabilities and cash flow improving together.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| PHG price | $27.57 at the July 8 close | StockAnalysis quote snapshot | July 11, 2026 |
| Market capitalization | $26.15 billion reported; $26.25 billion from $27.57 times 952.02M shares | StockAnalysis statistics and financial_rigor.py market-cap check | July 11, 2026 |
| Shares outstanding | 952.02 million | StockAnalysis statistics | July 11, 2026 |
| FY2025 revenue | EUR 17.834 billion | Philips 2025 Annual Report, cross-checked with StockAnalysis | July 11, 2026 |
| FY2025 net income | EUR 897 million | Philips 2025 Annual Report, cross-checked with StockAnalysis | July 11, 2026 |
| FY2025 free cash flow | EUR 512 million | Philips 2025 Annual Report | July 11, 2026 |
| FY2025 cash and cash equivalents | EUR 2.794 billion | Philips 2025 Annual Report, cross-checked with StockAnalysis | July 11, 2026 |
| FY2025 gross debt | EUR 8.084 billion | Philips 2025 Annual Report | July 11, 2026 |
| Q1 2026 performance | EUR 3.905 billion sales, 4% comparable sales growth, 9.0% adjusted EBITA margin, EUR 28 million free cash flow | Philips Q1 2026 results | July 11, 2026 |
| 2026 outlook | 3% to 4.5% comparable sales growth, 12.5% to 13.0% adjusted EBITA margin, EUR 1.3 to 1.5 billion free cash flow | Philips Q1 2026 results | July 11, 2026 |
| Respironics-related charges | EUR 209 million in 2025 | Philips 2025 Annual Report | July 11, 2026 |
This PHG AI stock analysis is an informational research tool, not investment, legal, tax, or trading advice. Forecast scenarios use available data and assumptions that can be wrong. Prices, technical levels, financial results, legal developments, and regulatory conditions can change quickly. Verify primary sources and consider professional advice before making an investment decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
